Download PDF
Dtsch Med Wochenschr 2012; 137(17): 894-899
DOI: 10.1055/s-0032-1304927
Aktuelle Diagnostik & Therapie | Review article
Neurologie
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Diagnostik und Therapie der Multiplen Sklerose

2012: Update on diagnosis and treatment of multiple sclerosis
J. Havla
1   Institut für Klinische Neuroimmunologie, Klinikum der Universität München, Grosshadern, Ludwig-Maximilians-Universität München
,
T. Kümpfel
1   Institut für Klinische Neuroimmunologie, Klinikum der Universität München, Grosshadern, Ludwig-Maximilians-Universität München
,
R. Hohlfeld
1   Institut für Klinische Neuroimmunologie, Klinikum der Universität München, Grosshadern, Ludwig-Maximilians-Universität München
› Author Affiliations
Further Information

Publication History

12 January 2012

22 March 2012

Publication Date:
10 April 2012 (online)

Also available at
    Permissions and Reprints

Corrected by:

Aktuelle Diagnostik und Therapie der Multiplen SkleroseDtsch Med Wochenschr 2012; 137(20): 1072-1072
DOI: 10.1055/s-0032-1301859

Schlüsselwörter

Multiple Sklerose - Diagnosekriterien - Schubtherapie - Basistherapie - Eskalationstherapie

Keywords

Multiple Sclerosis - immunomodulatory treatment - diagnostic criteria
 

  • Literatur

  • 1 Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2011; 68: 494-502
    PubMedGoogle Scholar
  • 2 Grauer O, Offenhausser M, Schmidt J et al. Glukokortikosteroid-Therapie bei Optikusneuritis und Multipler Sklerose. Evidenz aus klinischen Studien und praktischen Empfehlungen. Nervenarzt 2001; 72: 577-589
    CrossrefPubMedGoogle Scholar
  • 3 Havla J, Gerdes LA, Meinl I et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 2011; 258: 1665-1669
    CrossrefPubMedGoogle Scholar
  • 4 Havla J, Pellkofer HL, Meinl I et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 2012; 69: 262-264
    CrossrefPubMedGoogle Scholar
  • 5 Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 2011; 257: 580-583
    PubMedGoogle Scholar
  • 6 Henze T, Rieckmann P, Toyka KV. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Europ Neurol 2006; 56: 78-105
    CrossrefPubMedGoogle Scholar
  • 7 Klotz L, Gold R, Hemmer B et al. Diagnostik der Multiplen Sklerose 2010. Revision der McDonald-Kriterien. Nervenarzt 2011; 82: 1302-1309
    CrossrefPubMedGoogle Scholar
  • 8 Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911
    CrossrefPubMedGoogle Scholar
  • 9 Lucas RM, Ponsonby AL, Dear K et al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 2011; 77: 371-379
    CrossrefPubMedGoogle Scholar
  • 10 Martinelli V, Cocco E, Capra R et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011; 77: 1887-1895
    CrossrefPubMedGoogle Scholar
  • 11 Mauch E, Zwanzger J, Hettich R et al. Immunadsorption bei steroidrefraktärem Schub der Multiplen Sklerose. Klinische Erfahrung bei 14 Patienten. Nervenarzt 2011; 12: 1590-1595
    PubMedGoogle Scholar
  • 12 Mowry EM, James JA, Krupp LB et al. Vitamin D status and antibody levels to common viruses in pediatric-onset multiple sclerosis. Mult Scler 2011; 17: 666-671
    CrossrefPubMedGoogle Scholar
  • 13 O'Connor PW, Goodman A, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865
    CrossrefPubMedGoogle Scholar
  • 14 Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012; 366: 339-347
    CrossrefPubMedGoogle Scholar
  • 15 Polman CH, Bertolotto A, Deisenhammer F et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740-750
    CrossrefPubMedGoogle Scholar
  • 16 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
    CrossrefPubMedGoogle Scholar
  • 17 Sailer M, Fazekas F, Gass A et al. Zerebrale und spinale MRT-Untersuchung bei Patienten mit klinisch isoliertem Syndrom oder gesicherter Multipler Sklerose. Rofo 2008; 180: 994-1001
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219
    CrossrefPubMedGoogle Scholar
  • 19 Schroder A, Linker RA, Gold R. Plasmapheresis for neurological disorders. Expert Rev Neurother 2009; 9: 1331-1339
    CrossrefPubMedGoogle Scholar
  • 20 Smolders J, Menheere P, Kessels A et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008; 14: 1220-1224
    CrossrefPubMedGoogle Scholar
  • 21 Stroet A, Hemmelmann C, Starck M et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord 2012; 5: 75-79
    CrossrefPubMedGoogle Scholar
  • 22 Tumani H, Deisenhammer F, Giovannoni G et al. Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Ann Neurol 2011; 70: 520
    CrossrefPubMedGoogle Scholar
  • 23 Wade DT, Collin C, Stott C et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2011; 16: 707-714
    PubMedGoogle Scholar